dc.creatorConran, Nicola
dc.creatorOresco-Santos, Camila
dc.creatorAcosta, Heloisa C
dc.creatorFattori, André
dc.creatorSaad, Sara T O
dc.creatorCosta, Fernando F
dc.date2004-Feb
dc.date2015-11-27T12:58:45Z
dc.date2015-11-27T12:58:45Z
dc.date.accessioned2018-03-29T01:00:19Z
dc.date.available2018-03-29T01:00:19Z
dc.identifierBritish Journal Of Haematology. v. 124, n. 4, p. 547-54, 2004-Feb.
dc.identifier0007-1048
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/14984506
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/196131
dc.identifier14984506
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1296364
dc.descriptionActivation of soluble guanylate cyclase (sGC) has been reported to up-regulate gamma-globin gene transcription in erythroid cell lines and primary erythroblasts. sGC is activated by nitric oxide (NO), subsequently catalysing the conversion of guanosine triphosphate to cyclic guanosine monophosphate (cGMP), which mediates various physiological responses. To study the importance of this mechanism in the erythroid cells of sickle cell patients, cGMP levels were measured in the red blood cells (RBC) of normal individuals, steady-state sickle cell patients (SS) and SS patients on hydroxyurea (HU) therapy (SS + HU). cGMP levels were found to be significantly higher in RBC of SS patients (SS RBC) than in RBC of normal individuals, and were further increased in RBC of SS + HU patients. cGMP levels correlated with fetal haemoglobin (HbF) levels in SS/SS + HU patients, but not with reticulocyte count. Furthermore, NO-stimulated sGC activity, following incubation of cells with a NO donor, was significantly greater in SS RBC than in normal RBC. These results demonstrate, for the first time, an increased metabolism of NO mediated by sGC in the SS RBC, which is further increased by hydroxyurea. Augmentation of cGMP levels by NO in erythroid cells may constitute a mechanism for induction of HbF and other erythrocyte functions and represent a possible therapeutic target for treatment of sickle cell disease.
dc.description124
dc.description547-54
dc.languageeng
dc.relationBritish Journal Of Haematology
dc.relationBr. J. Haematol.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdult
dc.subjectAnemia, Sickle Cell
dc.subjectAntisickling Agents
dc.subjectChild
dc.subjectCyclic Gmp
dc.subjectErythrocytes
dc.subjectFemale
dc.subjectFetal Hemoglobin
dc.subjectGuanylate Cyclase
dc.subjectHumans
dc.subjectHydroxyurea
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNitric Oxide Donors
dc.subjectRna, Messenger
dc.subjectReticulocyte Count
dc.subjectReticulocytes
dc.subjectSolubility
dc.titleIncreased Soluble Guanylate Cyclase Activity In The Red Blood Cells Of Sickle Cell Patients.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución